Clinical Trial Update: Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating temozolomide plus vorinostat in relapse/refractory acute myeloid leukemia with 11q23 abnormalities; study completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia with 11q23-abnormality in Relapse

Drugs mentioned

• Temozolomide (Temozolomide)
• Vorinostat (vorinostat)

Snippet

Sponsor: Steven E. Coutre | Conditions: Acute Myeloid Leukemia With 11q23-abnormality in Relapse | Phase 2 | Status: COMPLETED | Results posted: 2018-07-16